Efficacy of Arthrotec® in the Treatment of Rheumatoid Arthritis
J. R. Haniwquin
Abstract
J. R. Haniwquin
Abstract
In a double-blind study, 346 patients with active rheumatoid arthritis were randomly assigned to receive Arthrotec®, a combination of 50 mg of diclofenac and 200 *g of misoprostol, or 50 mg of diclofenac; the drugs were given two or three times daily for 12 weeks. At weeks 4, 8. and 12 of treatment, no clinically significant differences between the two treatment groups were noted on measum of joint tenderness, pain, and swelling or on physicians' and patients' assessments of disease severity.
OpenAlex reports 6 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In a double-blind study, 346 patients with active rheumatoid arthritis were randomly assigned to receive Arthrotec®, a combination of 50 mg of diclofenac and 200 *g of misoprostol, or 50 mg of diclofenac; the drugs were given two or three times daily for 12 weeks. At weeks 4, 8. and 12 of treatment, no clinically significant differences between the two treatment groups were noted on measum of joint tenderness, pain, and swelling or on physicians' and patients' assessments of disease severity.
Key concepts: Medicine, Diclofenac, Rheumatoid arthritis, Misoprostol, Tenderness, Internal medicine, Arthritis, Joint pain